Importantly, a second infusion of CAR+IL-15-NK cells showed increased efficacy and allowed for more effective control of tumours [75] demonstrating that the treatment schedule of CAR-NK cells will need to be carefully assessed to optimize patient outcomes. Here, IL15 is linked to neoplasm.